Hyperekplexia Evaluation and Management
Hyperekplexia should be diagnosed clinically through the characteristic triad of exaggerated startle reflex, neonatal hypertonia, and generalized stiffness, with immediate treatment using clonazepam (0.1-0.2 mg/kg/day) to prevent potentially fatal apneic episodes and sudden infant death. 1
Clinical Recognition
The diagnosis is primarily clinical and should be suspected in any infant presenting with:
- Exaggerated startle response to stimuli (present in 67-100% of cases) 2
- Muscle stiffness/hypertonia (100% of cases) 2
- Positive nose-tapping test - repetitive nose tapping triggers sustained muscular rigidity with apnea 1
- Apnea/cyanosis episodes (42% of cases) 2
- Feeding difficulties with oropharyngeal incoordination 1
Critical Timing
Symptoms typically manifest within the first 24 hours of life (57% of cases), though diagnosis is often delayed by a median of 26 months due to misdiagnosis as epilepsy 3, 2. This delay is dangerous—three of 15 patients in one series died unexpectedly during the neonatal period when untreated 1.
Diagnostic Pitfall: Epilepsy Misdiagnosis
All patients (100%) in recent series were initially misdiagnosed with epilepsy 3. The key differentiator: EEG studies are consistently normal in hyperekplexia 1. The "tonic attacks" are nonepileptic and represent exaggerated startle responses, not seizures.
Genetic Testing
Once clinical diagnosis is established, genetic testing via Next-Generation Sequencing should identify the specific mutation:
- GLRA1 mutations (56-64% of cases) - typically respond well to clonazepam 3, 2
- SLC6A5 mutations (14-25% of cases) - generally respond well to clonazepam 3, 2
- GLRB mutations (14-19% of cases) - critical to identify as these patients show poor benzodiazepine response, require levetiracetam instead, and have worse outcomes with severe neurodevelopmental delay and autism spectrum features 3
- GPHN mutations (rare, 7% of cases) 2
Inheritance patterns include both autosomal dominant and recessive forms, with 50% showing familial occurrence 2, 4.
Immediate Management Algorithm
First-Line Treatment
Start clonazepam 0.1-0.2 mg/kg/day immediately upon clinical suspicion 1. Do not wait for genetic confirmation—the risk of sudden death is too high. Patients treated with clonazepam show:
- No serious apneic episodes
- Diminished startle reflexes
- Dramatic (though incomplete) symptom reduction 1, 4
If Poor Response to Clonazepam
Switch to levetiracetam, particularly if GLRB mutation is suspected or confirmed, as these patients are resistant to benzodiazepines 3.
Monitoring Requirements
- Continuous cardiorespiratory monitoring for at-risk infants until treatment is established 1
- Observe for apnea, aspiration pneumonia, and near-miss sudden infant death syndrome events 1
- The nose-tapping test should be included in routine newborn examinations to identify cases early 1
Neurophysiological Studies
While not required for diagnosis, nerve conduction studies and electromyography can help exclude other conditions in the differential (such as motor neuron disease presenting with hyperreflexia) 5. However, these are primarily useful for ruling out mimics rather than confirming hyperekplexia.
Prognosis
With appropriate treatment:
- Recurring apnea episodes resolve by 1 year of age 1
- Patients achieve age-appropriate milestones 6
- Quality of life improves significantly when epilepsy misdiagnosis is avoided 2
Exception: GLRB mutations carry a more severe prognosis with global neurodevelopmental delay and autism features despite treatment 3.